A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
RTOG 95-02 assessed patient tolerance to hypoxic cell radiosensitizer, etanidazole (SR-2508), combined with radiosurgery. Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation. The toxicity is reported in three groups of patients according to the tumor size. Etanidazole doses of 12g/m2 combined with radiosurgery were well tolerated.
Drzymala
R E
RE
Department of Radiation Oncology, Washington University Medical Center, St. Louis, MO 63110, USA. rdrzymala@radonc.wustl.edu
Wasserman
T H
TH
Won
M
M
Shaw
E
E
Cmelak
A J
AJ
Loeffler
J
J
Souhami
L
L
D000328:Adult; D001932:Brain Neoplasms / Q000532:radiotherapy* / Q000556:secondary / Q000601:surgery*; D003131:Combined Modality Therapy; D017341:Etanidazole / Q000627:therapeutic use*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D016634:Radiosurgery / Q000379:methods*; D011879:Radiotherapy Dosage; D015996:Survival Rate; D016896:Treatment Outcome
D011838:Radiation-Sensitizing Agents; D017341:Etanidazole